Business Context and Reporting Period
This Form 8-K was filed by Reneo Pharmaceuticals, Inc. (not Onkure Therapeutics, Inc.) on August 9, 2022. The filing serves to announce the Company's financial results for the second quarter ended June 30, 2022, along with recent corporate updates. The Company is an emerging growth company incorporated in Delaware and trades on the NASDAQ under the symbol RPHM.
Key Financial Metrics
The provided text is a cover page and index for the 8-K filing. It references a press release (Exhibit 99.1) containing the actual financial data but does not include the specific figures within this document.
- Revenue: Not provided in this text.
- Profit/Loss: Not provided in this text.
- Cash Flow: Not provided in this text.
- Margins: Not provided in this text.
- Debt and Liquidity: Not provided in this text.
Note: The filing text does not provide a clear value for any specific financial metric; these are contained in the referenced Exhibit 99.1.
Material Changes
The filing text does not detail specific material changes versus the prior comparable period. It only indicates that such results were reported in a press release issued on August 9, 2022.
Guidance, Outlook, and Risks
The text confirms the issuance of a press release regarding financial results and corporate updates but does not contain specific guidance, outlook statements, risk factors, or details on contingencies and unusual items. The information in Item 2.02 is furnished and not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the correct registrant name is Reneo Pharmaceuticals, Inc. (RPHM), as the input metadata incorrectly listed "Onkure Therapeutics, Inc."
- Review Exhibit 99.1 (Press Release) for the actual Q2 2022 financial figures, as they are absent from the 8-K cover page.
- Confirm the Company's status as an emerging growth company and its implications for financial reporting standards.
- Check the press release for specific details on "recent corporate updates" mentioned in Item 2.02.